Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy
Wellstone Center for FSHD
Cell Biology | Developmental Biology | Molecular Biology | Molecular Genetics | Musculoskeletal Diseases | Nervous System Diseases
INTRODUCTION: In preparation for future clinical trials, we determined the reliability, relationship to measures of disease severity, and consistency across sites of the 6 Minute Walk Test (6MWT) in patients with facioscapulohumeral muscular dystrophy (FSHD).
METHODS: Genetically defined and clinically affected FSHD participants at 2 sites performed the 6MWT, the Timed Up and Go, and the 30 foot Go/Timed 10 meter test as measures of mobility using standard procedures.
RESULTS: Eight-six participants representing the full range of severity performed the 6MWT. The mean 6MWT distance was 404.3 meters (SD 123.9), with no difference between sites. The 6MWT was reliable (n = 25; intraclass correlation coefficient = 0.99) and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score.
CONCLUSIONS: The 6MWT is reliable and is associated with other measures of FSHD disease severity. Future directions include assessing its sensitivity to disease progression. .
Rights and Permissions
Citation: Muscle Nerve. 2017 Mar;55(3):333-337. doi: 10.1002/mus.25251. Epub 2016 Dec 5. Link to article on publisher's site
6 Minute Walk Test, clinical trials, facioscapulohumeral muscular dystrophy, neuromuscular disease, outcome measures
Eichinger, Katy; Heatwole, Chad; Heininger, Susanne; Stinson, Nikia; Matichak Stock, Carly; Grosmann, Carla; Wagner, Kathryn R.; Tawil, Rabi; Statland, Jeffrey M.; and FSHD Clinical Trials Research Network, "Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy" (2017). Wellstone Center for FSHD Publications and Presentations. 37.